News Releases

A Penn Medicine and Children’s Hospital of Philadelphia (CHOP) team will seek to develop treatments for three rare, incurable genetic diseases with the help of a $26 million grant from the National Institutes of Health (NIH).

Researchers in the Perelman School of Medicine identified how genetic differences that alter a specific protein called ETS1 can affect our body's response to allergies.

A $25 million gift from an anonymous donor to Penn Medicine and Children’s Hospital of Philadelphia (CHOP) created a center to study epilepsy and neurodevelopmental disorders.

A grant from the Warren Alpert Foundation will allow Penn Medicine to create state-of-the-art online courses for genetic counselors to continue their education. Penn will work with four other institutions around the nation to create the new program.

Making it possible to directly order and work with the results of genetic testing through patients’ electronic health records – instead of through third-party portals – resulted in significant time savings for clinicians, according to a new study.

After mapping the genetic underpinning of kidney function in 1.5 million people and about 60,000 kidney cells that are the microscopic mechanisms of gene regulation, over 500 genes likely contribute to kidney disease development, according to researchers at the Perelman School of Medicine at the University of Pennsylvania.

The protein TCF-1 enables various parts of otherwise insulated DNA segments to intermingle in a way that is required for the development of T cells—a key element of the body’s immune system—and the role this protein plays in T cell creation could shed new light on immunotherapy approaches, according to a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania.

Generosity of Penn alumnus Michael Armellino creates center for care of patients with the rare genetic condition across all stages of life and propels scientific discovery

For the first time, researchers have revealed that during the development of Type 1 Diabetes (T1D), when insulin-producing cells in the pancreas are under attack from T lymphocytes, the cells lining the pancreatic duct reprogram themselves in an attempt to suppress autoimmune T cell responses.